News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Replimune and Incyte Announce Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Cutaneous Squamous Cell Carcinoma Patients
Tuesday, August 01, 2023Replimune Group Inc NASDAQ REPL and Incyte NASDAQ INCY have jointly announced a clinical trial collaboration and supply agreement
Ultragenyx Initiates Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial for UX701 Gene Therapy in Wilson Disease Treatment
Tuesday, August 01, 2023Ultragenyx Pharmaceutical Inc NASDAQ RARE recently announced the initiation of the second doseescalation cohort in its pivotal Phase Cyprus study after completing dosing and safety review in the first cohort
Biohaven's Taldefgrobep Alfa Granted EU Orphan Drug Designation for Spinal Muscular Atrophy
Tuesday, August 01, 2023Biohaven Ltd NYSE BHVN has recently obtained orphan medicinal product designation from the European Commission EC for taldefgrobep alfa a novel antimyostatin adnectin aimed at treating spinal muscular atrophy SMA
Marinus Pharmaceuticals Receives European Commission Approval for ZTALMY® (Ganaxolone) as Adjunctive Therapy for Epileptic Seizures Associated With CDKL5 Deficiency Disorder
Monday, July 31, 2023Marinus Pharmaceuticals Inc Nasdaq MRNS has received approval from the European Commission EC for the oral suspension medication ZTALMY ganaxolone
Ionis Completes Enrollment in Pivotal Phase 3 CARDIO-TTRansform Trial for Patients With TTR-mediated Amyloid Cardiomyopathy
Monday, July 31, 2023Ionis Pharmaceuticals Inc Nasdaq IONS has successfully completed the enrollment phase of the Phase CARDIOTTRansform cardiovascular outcomes study for eplontersen an investigational drug targeting transthyretinmediated amyloid cardiomyopathy ATTRCM
TFF Pharmaceuticals Inc. And Uniphar Durbin Ireland Ltd. Announce the Launch of Expanded Access Program for Voriconazole Inhalation Powder
Monday, July 31, 2023Uniphar Durbin Ireland Limited Durbin or the Company and TFF Pharmaceuticals Inc Nasdaq TFFP have jointly announced the launch of an Expanded Access Program EAP for TFFVORI
Genenta's Ongoing Clinical Trial Progress and Ambitious Plans for Solid Tumor Treatments
Saturday, July 29, 2023Genenta Science NASDAQ GNTA has provided an update on its clinicalstage immunooncology IO efforts focusing on the development of Temferon a cellbased platform aimed at providing safe and durable treatments for solid tumors
FDA Grants Breakthrough Therapy Designation to NS-089/NCNP-02 for Duchenne Muscular Dystrophy Treatment
Saturday, July 29, 2023NS Pharma Inc announced today that the US Food Drug Administration FDA has granted Breakthrough Therapy Designation to NSNCNP an investigational candidate developed for patients with Duchenne muscular dystrophy amenable to exon skipping therapy
IO Biotech Commences Phase 1 Trial, Administers First Dose to Patient at University of California Davis Comprehensive Cancer Center
Saturday, July 29, 2023IO Biotech Nasdaq IOBT has recently announced the initiation of an investigatorinitiated trial in collaboration with the University of California Davis Comprehensive Cancer Center
Celularity and Verséa Ophthalmics Establish Exclusive Agreement to Commercialize Biovance® and Biovance® 3L Ocular for Ophthalmic Applications in the U.S.
Friday, July 28, 2023Celularity Inc Nasdaq CELU and Versa Ophthalmics LLC have entered into an exclusive US commercialization agreement according to their joint announcement Versa Ophthalmics a company based in Tampa FL specializes in delivering complete ocular pointofca...
